CN114025742A - 用于眼部疾病的治疗的组合物和方法 - Google Patents

用于眼部疾病的治疗的组合物和方法 Download PDF

Info

Publication number
CN114025742A
CN114025742A CN202080044610.5A CN202080044610A CN114025742A CN 114025742 A CN114025742 A CN 114025742A CN 202080044610 A CN202080044610 A CN 202080044610A CN 114025742 A CN114025742 A CN 114025742A
Authority
CN
China
Prior art keywords
antibiotic
hydrogel
ophthalmic composition
hyaluronic acid
moxifloxacin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080044610.5A
Other languages
English (en)
Chinese (zh)
Inventor
布伦达·K·曼
李熙京
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kiora Pharmaceuticals Inc
Original Assignee
EyeGate Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EyeGate Pharmaceuticals Inc filed Critical EyeGate Pharmaceuticals Inc
Publication of CN114025742A publication Critical patent/CN114025742A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080044610.5A 2019-05-03 2020-04-30 用于眼部疾病的治疗的组合物和方法 Pending CN114025742A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962842995P 2019-05-03 2019-05-03
US62/842,995 2019-05-03
PCT/US2020/030691 WO2020227002A1 (en) 2019-05-03 2020-04-30 Compositions and methods for treatment of ocular diseases

Publications (1)

Publication Number Publication Date
CN114025742A true CN114025742A (zh) 2022-02-08

Family

ID=70861542

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080044610.5A Pending CN114025742A (zh) 2019-05-03 2020-04-30 用于眼部疾病的治疗的组合物和方法

Country Status (9)

Country Link
US (2) US11376214B2 (https=)
EP (1) EP3962452A1 (https=)
JP (1) JP7334266B2 (https=)
KR (2) KR102649858B1 (https=)
CN (1) CN114025742A (https=)
CA (1) CA3139060A1 (https=)
IL (1) IL287802B2 (https=)
MX (1) MX2021013447A (https=)
WO (1) WO2020227002A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10945858B2 (en) * 2010-09-03 2021-03-16 Globus Medical, Inc. Expandable interspinous process fixation device
GB202008857D0 (en) * 2020-06-11 2020-07-29 Univ Birmingham Fluid gel compositions
GB202008853D0 (en) * 2020-06-11 2020-07-29 Univ Birmingham Fluid gel compositions
CN112587475B (zh) * 2020-12-18 2022-09-13 华熙生物科技股份有限公司 一种载药凝胶及其制备方法
DE102023116924A1 (de) * 2023-06-27 2025-01-02 Carl Zeiss Meditec Ag Kit zur Verwendung in einer Augenoperation und ophthalmische viskoelastische Vorrichtung
WO2025155730A1 (en) * 2024-01-16 2025-07-24 Regents Of The University Of Minnesota Injectable hydrogel for embolization

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020128512A1 (en) * 2001-02-22 2002-09-12 Anika Therapeutics, Inc. Thiol- modified hyaluronan
CA2703807A1 (en) * 2010-05-12 2011-11-12 Molly S. Shoichet Enhanced stability of inverse thermal gelling composite hydrogels
US20140341842A1 (en) * 2013-05-14 2014-11-20 Bio Time, Inc. Thiolated hyaluronan-based hydrogels cross-linked using oxidized glutathione
US20150157563A1 (en) * 2013-10-17 2015-06-11 Jade Therapeutics, Inc Ocular composition and method

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3675873A4 (en) * 2017-09-01 2021-06-16 Pmidg, Llc Functionalized and crosslinked polymers
US12029753B2 (en) * 2017-09-19 2024-07-09 The Hong Kong University Of Science And Technology Biocompatible material and methods for making and using thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020128512A1 (en) * 2001-02-22 2002-09-12 Anika Therapeutics, Inc. Thiol- modified hyaluronan
CA2703807A1 (en) * 2010-05-12 2011-11-12 Molly S. Shoichet Enhanced stability of inverse thermal gelling composite hydrogels
US20140341842A1 (en) * 2013-05-14 2014-11-20 Bio Time, Inc. Thiolated hyaluronan-based hydrogels cross-linked using oxidized glutathione
US20150157563A1 (en) * 2013-10-17 2015-06-11 Jade Therapeutics, Inc Ocular composition and method

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WENDLING RJ,等: "Effect of Carboxymethylation on the Rheological Properties of Hyaluronan", 《PLOS ONE》 *

Also Published As

Publication number Publication date
IL287802B1 (en) 2024-05-01
MX2021013447A (es) 2022-02-11
KR20220004753A (ko) 2022-01-11
WO2020227002A1 (en) 2020-11-12
CA3139060A1 (en) 2020-11-12
JP7334266B2 (ja) 2023-08-28
IL287802A (en) 2022-01-01
US20200345634A1 (en) 2020-11-05
US11376214B2 (en) 2022-07-05
KR20240038152A (ko) 2024-03-22
JP2022530837A (ja) 2022-07-01
EP3962452A1 (en) 2022-03-09
IL287802B2 (en) 2024-09-01
US20220287961A1 (en) 2022-09-15
KR102649858B1 (ko) 2024-03-20

Similar Documents

Publication Publication Date Title
US20220287961A1 (en) Compositions and methods for treatment of ocular diseases
CN107847604B (zh) 眼用原位凝胶处方
US9782345B2 (en) Ocular composition and method
JP2021121608A (ja) 抗菌剤及び抗炎症剤を含む眼内投与のための医薬組成物
Alase Sustained ophthalmic delivery of gatifloxacin from in situ gelling system
WO2019169221A1 (en) Nitric oxide releasing suppositories and methods of use thereof
CN108883081A (zh) 蛋白酶体抑制剂治疗眼部疾病的用途
TW200918075A (en) Compositions and methods for modulating endophthalmitis using fluoroquinolones
JP2023518972A (ja) 眼病態の治療のための組成物及び方法
EP4021402A1 (en) Thixotropic delivery systems
US9814673B2 (en) Intraocular lens comprising pharmaceutical compositions and methods for fabricating thereof
EP4356929A1 (en) Antifibrotic formulation for ophthalmic treatment
CN119326771A (zh) 包含泊洛沙姆的眼科组合物
CN118121709A (zh) 一种眼用药物组合物及其制备方法、应用
CA3119363A1 (en) Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
HK1248100B (zh) 眼用原位凝胶处方
Khan Formulation and Evaluation of Controlled Release Ocular Inserts of Erythromycin
NZ514568A (en) Ophthalmic compositions comprising carboxylic acid polymer-cyclodextrin conjugate like PAA-CD (polyacrylic acid cyclodextrin) and active drug

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20220208